Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.

Medicina (Kaunas, Lithuania) - 30 Sept 2021

Giai Valentina, Secreto Carolina, Freilone Roberto, Pregno Patrizia

Abstract excerpt

Philadelphia negative Myeloproliferative Neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell diseases. MPNs show different risk grades of thrombotic complications and acute myeloid leukemia evolution. In the last couple of decades, from JAK2 mutation detection in 2005 to the newer molecular trademarks studied through next generation sequencing, we are learning to approach MPNs from a deeper...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cells
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myeloproliferative Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 34684081
DOI: 10.3390/medicina57101043
PMCID: PMC8537741

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.PMID 34684081Read ↗

Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Molecular profiling in MPN: who should have it and why?Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

Molecular pathogenesis of the myeloproliferative neoplasms.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.